SARS-CoV-2 患者的抗凝使用与出血性卒中:纽约医疗系统经验
该回顾性队列研究纳入2020年3月1日至5月15日纽约某大型医疗系统内住院的出血性卒中患者,比较合并COVID-19者与同期及2019年历史对照的临床特征。4071例COVID-19住院患者中19例(0.5%)发生出血性卒中,其中凝血病为最常见病因(73.7%),89.5%已启动经验性抗凝(同期对照4.2%,历史对照10.0%,均p≤.001)。COVID-19组初始NIHSS评分、INR、PTT及纤维蛋白原水平更高,院内死亡率84.6% vs 4.6%(p≤0.001)。作者认为需进一步研究COVID-19治疗性抗凝的安全性与有效性。
要点
- 4071例COVID-19住院患者中19例(0.5%)发生影像确诊出血性卒中,仅3例为孤立性非动脉瘤性蛛网膜下腔出血。
- COVID-19合并出血性卒中者凝血病为最常见病因(73.7%),89.5%已启动经验性抗凝,显著高于同期对照4.2%和历史对照10.0%(均p≤.001)。
- 与同期及历史对照相比,COVID-19组初始NIHSS评分、INR、PTT及纤维蛋白原水平更高。
- COVID-19组合并出血性卒中者院内死亡率84.6%,显著高于对照4.6%(p≤0.001);排除单纯蛛网膜下腔出血的敏感性分析结果相似。
- 作者认为需进一步研究评估COVID-19治疗性抗凝的安全性与有效性。
适用人群与场景
- 2020年3月1日至5月15日在纽约某大型医疗系统内住院、发生出血性卒中(非创伤性颅内出血和自发性非动脉瘤性蛛网膜下腔出血)的患者,包括入院时即有出血和住院期间新发出血者。
- 对照组为同期(2020年3月1日至5月15日)及历史(2019年3月1日至5月15日)在该医疗系统住院的出血性卒中患者。
研究设计与关键结果
- 研究类型:回顾性队列研究;2020年研究期内4071例COVID-19住院患者中识别出19例(0.5%)出血性卒中,其中仅3例为孤立性非动脉瘤性蛛网膜下腔出血无脑实质出血。
- COVID-19合并出血性卒中者凝血病为最常见病因(73.7%);经验性抗凝启动比例89.5%,同期对照4.2%(p≤.001),历史对照10.0%(p≤.001)。
- 与同期及历史对照相比,COVID-19组初始NIHSS评分、INR、PTT及纤维蛋白原水平更高。
- COVID-19组院内死亡率84.6% vs 对照4.6%(p≤0.001);排除单纯蛛网膜下腔出血患者的敏感性分析结果相似。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为需进一步研究评估COVID-19治疗性抗凝的安全性与有效性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: While the thrombotic complications of COVID-19 have been well described, there are limited data on clinically significant bleeding complications including hemorrhagic stroke. The clinical characteristics, underlying stroke mechanism, and outcomes in this particular subset of patients are especially salient as therapeutic anticoagulation becomes increasingly common in the treatment and prevention of thrombotic complications of COVID-19.
METHODS: We conducted a retrospective cohort study of patients with hemorrhagic stroke (both non-traumatic intracerebral hemorrhage and spontaneous non-aneurysmal subarachnoid hemorrhage) who were hospitalized between March 1, 2020, and May 15, 2020, within a major healthcare system in New York, during the coronavirus pandemic. Patients with hemorrhagic stroke on admission and who developed hemorrhage during hospitalization were both included. We compared the clinical characteristics of patients with hemorrhagic stroke and COVID-19 to those without COVID-19 admitted to our hospital system between March 1, 2020, and May 15, 2020 (contemporary controls), and March 1, 2019, and May 15, 2019 (historical controls). Demographic variables and clinical characteristics between the individual groups were compared using Fischer's exact test for categorical variables and nonparametric test for continuous variables. We adjusted for multiple comparisons using the Bonferroni method.
RESULTS: During the study period in 2020, out of 4071 patients who were hospitalized with COVID-19, we identified 19 (0.5%) with hemorrhagic stroke. Of all COVID-19 with hemorrhagic stroke, only three had isolated non-aneurysmal SAH with no associated intraparenchymal hemorrhage. Among hemorrhagic stroke in patients with COVID-19, coagulopathy was the most common etiology (73.7%); empiric anticoagulation was started in 89.5% of these patients versus 4.2% in contemporary controls (p ≤ .001) and 10.0% in historical controls (p ≤ .001). Compared to contemporary and historical controls, patients with COVID-19 had higher initial NIHSS scores, INR, PTT, and fibrinogen levels. Patients with COVID-19 also had higher rates of in-hospital mortality (84.6% vs. 4.6%, p ≤ 0.001). Sensitivity analyses excluding patients with strictly subarachnoid hemorrhage yielded similar results.
CONCLUSION: We observed an overall low rate of imaging-confirmed hemorrhagic stroke among patients hospitalized with COVID-19. Most hemorrhages in patients with COVID-19 infection occurred in the setting of therapeutic anticoagulation and were associated with increased mortality. Further studies are needed to evaluate the safety and efficacy of therapeutic anticoagulation in patients with COVID-19.
参考来源
- Kvernland A, Kumar A, Yaghi S, et al. Anticoagulation use and Hemorrhagic Stroke in SARS-CoV-2 Patients Treated at a New York Healthcare System. Neurocrit Care. 2020. PMID: 32839867. doi:10.1007/s12028-020-01077-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。